Cutaneous Radiation Injury Treatment: Market Insights
Cutaneous radiation injury occurs on a functional, cellular, and gross level. Radiation therapy is the major modality in the management of cancer treatment along with the surgery and chemotherapy. Most common side effect of the radiation is the acute skin reaction which usually range from mild to confluent moist desquamation. Patients receiving external radiation therapy are at potential risk of developing cutaneous radiation injury within the treatment area with 85-87% of patient’s experience moderate severe skin reaction. Cutaneous radiation injury occur to the skin and tissues which is caused due to acute radiation doses which is low as 3Gy. Cutaneous radiation injury occur along with the acute radiation injury or focal radiation exposure. Emergence of new technology and development of new treatment option available will further drive the growth of cutaneous radiation therapy treatment market.
Download sample copy of this report:
Cutaneous Radiation Injury Treatment: Market Dynamics
With increasing use of radiation therapy for the treatment of cancer and longer survival of the patients, lead to cutaneous radiation injury where there is change in the tissues and tumors in the area where radiation therapy is given which significantly increase the market for cutaneous radiation injury treatment in the forecast period. Growing prevalence of cancer among population, growing number of cardiovascular surgeries, and growing adoption of radiation therapy particularly in the middle and low income economies further spur the cutaneous radiation injury treatment market. Favorable reimbursement scenarios and government initiative towards the treatment for disease which are growing rapidly such as cancer will further lead to the growth of cutaneous radiation injury treatment market. Emergence of new treatment option for the cutaneous radiation injury will further fuel the cutaneous radiation injury treatment market globally
Despite many factors which drive the global market for cutaneous radiation injury treatment, certain barriers which limits the growth of the cutaneous radiation therapy treatment market include lack of awareness among patients with the available treatment option. Development of new emerging radiation therapy devices which have less side effects will further hinder the growth of cutaneous radiation injury treatment market
Cutaneous Radiation Injury Treatment: Segmentation
The global cutaneous radiation injury treatment market is segmented on basis of exposure type, stage, route of administration, drug type, distribution channel and geography.
- Segmentation by Exposure Type
- Segmentation by Stage
- Prodromal stage
- Latent stage
- Manifest illness stage
- Third wave of erythema
- Segmentation by Route of Administration
- Segmentation by Drug Type
- Nonsteroidal anti-inflammatory drugs
- Segmentation by Distribution Channel
- Hospitals Pharmacies
- Drug Stores
- Retail Pharmacies
- Mail Order Pharmacies
Cutaneous Radiation Injury Treatment: Overview
Advances in the technology and development of new therapeutic regimens for the cutaneous radiation injury treatment creates huge opportunity for the cutaneous radiation injury treatment market to grow in the forecast period. Advancements with targeted therapies for reducing the underlying inflammatory cascade, such as superoxide dismutase/catalase mimetic to decrease reactive oxygen species and interleukin inhibitors will further drive the cutaneous radiation injury treatment market.
Cutaneous Radiation Injury Treatment: Region-wise Outlook
The North America is expected to contribute to a major share in the global cutaneous radiation injury treatment, owing to increasing incidence of cancer, growing demand of radiation therapy. Healthy reimbursement policies and well developed healthcare facilities further drive the market for cutaneous radiation injury treatment. Europe contributes for the second largest share with significant growth in the global cutaneous radiation injury treatment market owing to technological advancement in the treatment for cancer coupled with growing adoption of new treatment regimen and undergoing clinical trial for the development of new drug for cutaneous radiation injury treatment. Asia Pacific market is primarily driven by the factors such as rising expenditure of healthcare systems, improvement in the healthcare facilities and growing prevalence of cancer and awareness of new treatment options. China is expected to register significant growth in the cutaneous radiation injury treatment market, due to large patient pool, low cost of treatment, availability of newly developed drugs for the cutaneous radiation injury treatment. Latin America and Middle East & Africa are projected to show sluggish growth in cutaneous radiation injury treatment market, due to less awareness, lack of adoption of new advanced technology and lack of adequate healthcare facilities.
Download Data Set @
Cutaneous Radiation Injury Treatment: Key Players
Some of the key players present in the global cutaneous radiation injury treatment market are Merck & Co., Novartis AG, Johnson and Johnson, Pfizer Inc. Amgen, Hoffmann-La Roche Ltd, Eli Lily and Company, AstraZeneca and Teva Pharmaceutical among others.